Arrowhead Pharmaceuticals, Inc. (ARWR) vs Krystal Biotech, Inc. (KRYS)

Arrowhead Pharmaceuticals, Inc. and Krystal Biotech, Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. and Krystal Biotech, Inc. are of similar size ($10.2B and $9.3B). Arrowhead Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Krystal Biotech, Inc. trades at 41.9×. Krystal Biotech, Inc. grew revenue faster over the last twelve months: 22.6% against 16.1%. Krystal Biotech, Inc. has the higher net margin (54.8% vs −47.8%) and the higher return on invested capital (24.1% vs 0.00%). Across the 17 metrics below, Krystal Biotech, Inc. leads on 13 and Arrowhead Pharmaceuticals, Inc. on 4.

Valuation

Metric ARWR KRYS Biotechnology median
P/E n/m 41.86 7.88
P/S 14.12 23.21 11.47
P/B 20.28 7.52 2.52
Price to free cash flow n/m 39.65 21.16
EV/EBITDA n/m 45.87 0.74
EV/Sales 13.02 21.29 10.73
Earnings yield (3.41%) 2.39% (28.84%)
Free cash flow yield (0.79%) 2.52% (23.03%)

Profitability

Metric ARWR KRYS Biotechnology median
Gross margin 100.00% 94.64% 65.16%
Operating margin (33.82%) 44.89% 0.00%
Net margin (47.79%) 54.82% 0.00%
Free cash flow margin (11.22%) 58.52% 0.00%
Return on equity (64.91%) 20.12% (57.72%)
Return on assets (18.32%) 18.30% (49.22%)
Return on invested capital 0.00% 24.07% 0.00%

Growth

Metric ARWR KRYS Biotechnology median
Revenue growth (TTM) 16.13% 22.63% 5.64%
EPS growth (last fiscal year) 99.80% 128.00% —
Revenue growth, 5-year CAGR 56.63% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARWR KRYS Biotechnology median
Debt to equity 1.85 0.00 0.00
Current ratio 5.90 8.32 4.73
Net debt to EBITDA (5.70) (4.93) 0.96

Dividend

Metric ARWR KRYS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARWR KRYS Biotechnology median
Market cap 9.33b 10.21b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack